The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Apressin     phthalazin-1-ylhydrazine

Synonyms: Apresolin, Aprezolin, Apresoline, Hidral, Hidralazin, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Apresoline


Psychiatry related information on Apresoline


High impact information on Apresoline


Chemical compound and disease context of Apresoline


Biological context of Apresoline


Anatomical context of Apresoline


Associations of Apresoline with other chemical compounds


Gene context of Apresoline


Analytical, diagnostic and therapeutic context of Apresoline


  1. Association of antibody to histone complex H2A-H2B with symptomatic procainamide-induced lupus. Totoritis, M.C., Tan, E.M., McNally, E.M., Rubin, R.L. N. Engl. J. Med. (1988) [Pubmed]
  2. Tolerance ot hydralazine in congestive heart failure. Bussey, H.I. N. Engl. J. Med. (1982) [Pubmed]
  3. Hydralazine-induced neonatal thrombocytopenia. Widerlöv, E., Karlman, I., Storsäter, J. N. Engl. J. Med. (1980) [Pubmed]
  4. Evaluation of a new antihypertensive agent: prazosin hydrochloride (Minipress). Kosman, M.E. JAMA (1977) [Pubmed]
  5. Hydralazine-induced tumor hypoxia: a potential target for cancer chemotherapy. Chaplin, D.J. J. Natl. Cancer Inst. (1989) [Pubmed]
  6. REM sleep inhibition by desipramine: evidence for an alpha-1 adrenergic mechanism. Ross, R.J., Gresch, P.J., Ball, W.A., Sanford, L.D., Morrison, A.R. Brain Res. (1995) [Pubmed]
  7. The renin angiotensin system and nociception in spontaneously hypertensive rats. Irvine, R.J., White, J.M., Head, R.J. Life Sci. (1995) [Pubmed]
  8. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. Cohn, J.N., Johnson, G., Ziesche, S., Cobb, F., Francis, G., Tristani, F., Smith, R., Dunkman, W.B., Loeb, H., Wong, M. N. Engl. J. Med. (1991) [Pubmed]
  9. Deleterious effects of hydralazine in patients with pulmonary hypertension. Packer, M., Greenberg, B., Massie, B., Dash, H. N. Engl. J. Med. (1982) [Pubmed]
  10. Hydralazine and the treatment of primary pulmonary hypertension. Kadowitz, P.J., Hyman, A.L. N. Engl. J. Med. (1982) [Pubmed]
  11. Hemodynamic characterization of tolerance to long-term hydralazine therapy in severe chronic heart failure. Packer, M., Meller, J., Medina, N., Yushak, M., Gorlin, R. N. Engl. J. Med. (1982) [Pubmed]
  12. Oral hydralazine therapy for primary pulmonary hypertension. Rubin, L.J., Peter, R.H. N. Engl. J. Med. (1980) [Pubmed]
  13. Complement system protein C4 and susceptibility to hydralazine-induced systemic lupus erythematosus. Speirs, C., Fielder, A.H., Chapel, H., Davey, N.J., Batchelor, J.R. Lancet (1989) [Pubmed]
  14. Effect of isosorbide and hydralazine in painful primary esophageal motility disorders. Mellow, M.H. Gastroenterology (1982) [Pubmed]
  15. Artefacts in measurement of blood pressure and lack of target organ involvement in the assessment of patients with treatment-resistant hypertension. Mejia, A.D., Egan, B.M., Schork, N.J., Zweifler, A.J. Ann. Intern. Med. (1990) [Pubmed]
  16. Prazosin and hydralazine in congestive heart failure. Regional hemodynamic effects in relation to dose. Magorien, R.D., Triffon, D.W., Desch, C.E., Bay, W.H., Unverferth, D.V., Leier, C.V. Ann. Intern. Med. (1981) [Pubmed]
  17. Hemodynamic effects of nitroprusside and hydralazine in experimental cardiac tamponade. Fowler, N.O., Gabel, M., Holmes, J.C. Circulation (1978) [Pubmed]
  18. Suppression of mesangial proliferative glomerulonephritis development in rats by inhibitors of cAMP phosphodiesterase isozymes types III and IV. Tsuboi, Y., Shankland, S.J., Grande, J.P., Walker, H.J., Johnson, R.J., Dousa, T.P. J. Clin. Invest. (1996) [Pubmed]
  19. Effects of hydralazine-induced vasodilation on the energy metabolism of murine tumors studied by in vivo 31P-nuclear magnetic resonance spectroscopy. Okunieff, P., Kallinowski, F., Vaupel, P., Neuringer, L.J. J. Natl. Cancer Inst. (1988) [Pubmed]
  20. Treating activated CD4+ T cells with either of two distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice. Quddus, J., Johnson, K.J., Gavalchin, J., Amento, E.P., Chrisp, C.E., Yung, R.L., Richardson, B.C. J. Clin. Invest. (1993) [Pubmed]
  21. Rest and exercise hemodynamic effects of oral hydralazine in patients with coronary artery disease and left ventricular dysfunction. Hindman, M.C., Slosky, D.A., Peter, R.H., Newman, G.E., Jones, R.H., Wallace, A.G. Circulation (1980) [Pubmed]
  22. Vasodilative effect of hydralazine in awake dogs: the roles of prostaglandins and the sympathetic nervous system. Maekawa, K., Liang, C.S., Tsui, A., Chen, B.T., Kawashima, S. Circulation (1984) [Pubmed]
  23. Relationship between the genetically determined acetylator phenotype and DNA damage induced by hydralazine and 2-aminofluorene in cultured rabbit hepatocytes. McQueen, C.A., Maslansky, C.J., Glowinski, I.B., Crescenzi, S.B., Weber, W.W., Williams, G.M. Proc. Natl. Acad. Sci. U.S.A. (1982) [Pubmed]
  24. Enhanced endothelial adhesiveness in hypercholesterolemia is attenuated by L-arginine. Tsao, P.S., McEvoy, L.M., Drexler, H., Butcher, E.C., Cooke, J.P. Circulation (1994) [Pubmed]
  25. Altered renin release and propranolol potentiation of vasodilatory drug hypotension. Pettinger, W.A., Keeton, K. J. Clin. Invest. (1975) [Pubmed]
  26. Tumorigenic effect of 1-hydrazinophthalazine hydrochloride in mice. Toth, B. J. Natl. Cancer Inst. (1978) [Pubmed]
  27. Abnormal response of tumor vasculature to vasoactive drugs. Chan, R.C., Babbs, C.F., Vetter, R.J., Lamar, C.H. J. Natl. Cancer Inst. (1984) [Pubmed]
  28. Use of fluorine-19 nuclear magnetic resonance spectroscopy and hydralazine for measuring dynamic changes in blood perfusion volume in tumors in mice. Thomas, C., Counsell, C., Wood, P., Adams, G.E. J. Natl. Cancer Inst. (1992) [Pubmed]
  29. Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling. Deng, C., Lu, Q., Zhang, Z., Rao, T., Attwood, J., Yung, R., Richardson, B. Arthritis Rheum. (2003) [Pubmed]
  30. The SOD mimetic tempol ameliorates glomerular injury and reduces mitogen-activated protein kinase activity in Dahl salt-sensitive rats. Nishiyama, A., Yoshizumi, M., Hitomi, H., Kagami, S., Kondo, S., Miyatake, A., Fukunaga, M., Tamaki, T., Kiyomoto, H., Kohno, M., Shokoji, T., Kimura, S., Abe, Y. J. Am. Soc. Nephrol. (2004) [Pubmed]
  31. Eukaryotic arylamine N-acetyltransferase. Investigation of substrate specificity by high-throughput screening. Kawamura, A., Graham, J., Mushtaq, A., Tsiftsoglou, S.A., Vath, G.M., Hanna, P.E., Wagner, C.R., Sim, E. Biochem. Pharmacol. (2005) [Pubmed]
  32. Drug-induced immune-complex disease. Sim, E. Complement and inflammation. (1989) [Pubmed]
  33. Importance of left ventricular chamber size in determining the response to hydralazine in severe chronic heart failure. Packer, M., Meller, J., Medina, N., Gorlin, R., Herman, M.V. N. Engl. J. Med. (1980) [Pubmed]
  34. Induction of antibodies to nuclear antigens in rabbits by immunization with hydralazine-human serum albumin conjugates. Yamauchi, Y., Litwin, A., Adams, L., Zimmer, H., Hess, E.V. J. Clin. Invest. (1975) [Pubmed]
  35. Significance of systemic vascular resistance in determining the hemodynamic effects of hydralazine on large ventricular septal defects. Nakazawa, M., Takao, A., Chon, Y., Shimizu, T., Kanaya, M., Momma, K. Circulation (1983) [Pubmed]
WikiGenes - Universities